PMC:7267243 / 8195-8825 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"246","span":{"begin":272,"end":281},"obj":"Species"},{"id":"247","span":{"begin":122,"end":135},"obj":"Chemical"},{"id":"248","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"249","span":{"begin":282,"end":291},"obj":"Disease"},{"id":"250","span":{"begin":297,"end":301},"obj":"Disease"},{"id":"251","span":{"begin":343,"end":359},"obj":"Disease"}],"attributes":[{"id":"A246","pred":"tao:has_database_id","subj":"246","obj":"Tax:2697049"},{"id":"A247","pred":"tao:has_database_id","subj":"247","obj":"MESH:C012990"},{"id":"A248","pred":"tao:has_database_id","subj":"248","obj":"MESH:C000657245"},{"id":"A249","pred":"tao:has_database_id","subj":"249","obj":"MESH:D007239"},{"id":"A250","pred":"tao:has_database_id","subj":"250","obj":"MESH:D012128"},{"id":"A251","pred":"tao:has_database_id","subj":"251","obj":"MESH:D007153"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157)."}

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T12","span":{"begin":209,"end":214},"obj":"Body_part"}],"attributes":[{"id":"A12","pred":"fma_id","subj":"T12","obj":"http://purl.org/sig/ont/fma/fma63083"}],"text":"COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157)."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T6","span":{"begin":209,"end":214},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"uberon_id","subj":"T6","obj":"http://purl.obolibrary.org/obo/UBERON_0001977"}],"text":"COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T94","span":{"begin":0,"end":8},"obj":"Disease"},{"id":"T95","span":{"begin":154,"end":156},"obj":"Disease"},{"id":"T96","span":{"begin":272,"end":276},"obj":"Disease"},{"id":"T97","span":{"begin":282,"end":291},"obj":"Disease"},{"id":"T98","span":{"begin":297,"end":301},"obj":"Disease"},{"id":"T99","span":{"begin":334,"end":359},"obj":"Disease"},{"id":"T100","span":{"begin":343,"end":359},"obj":"Disease"}],"attributes":[{"id":"A94","pred":"mondo_id","subj":"T94","obj":"http://purl.obolibrary.org/obo/MONDO_0100096"},{"id":"A95","pred":"mondo_id","subj":"T95","obj":"http://purl.obolibrary.org/obo/MONDO_0017991"},{"id":"A96","pred":"mondo_id","subj":"T96","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A97","pred":"mondo_id","subj":"T97","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"},{"id":"A98","pred":"mondo_id","subj":"T98","obj":"http://purl.obolibrary.org/obo/MONDO_0006502"},{"id":"A99","pred":"mondo_id","subj":"T99","obj":"http://purl.obolibrary.org/obo/MONDO_0017769"},{"id":"A100","pred":"mondo_id","subj":"T100","obj":"http://purl.obolibrary.org/obo/MONDO_0021094"}],"text":"COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T73","span":{"begin":20,"end":23},"obj":"Chemical"},{"id":"T75","span":{"begin":122,"end":135},"obj":"Chemical"},{"id":"T76","span":{"begin":154,"end":156},"obj":"Chemical"}],"attributes":[{"id":"A73","pred":"chebi_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/CHEBI_17824"},{"id":"A74","pred":"chebi_id","subj":"T73","obj":"http://purl.obolibrary.org/obo/CHEBI_30802"},{"id":"A75","pred":"chebi_id","subj":"T75","obj":"http://purl.obolibrary.org/obo/CHEBI_27680"},{"id":"A76","pred":"chebi_id","subj":"T76","obj":"http://purl.obolibrary.org/obo/CHEBI_74824"}],"text":"COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157)."}

{"project":"LitCovid-PD-GlycoEpitope","denotations":[{"id":"T2","span":{"begin":122,"end":135},"obj":"GlycoEpitope"}],"attributes":[{"id":"A2","pred":"glyco_epitope_db_id","subj":"T2","obj":"http://www.glycoepitope.jp/epitopes/EP0510"}],"text":"COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T102","span":{"begin":0,"end":261},"obj":"Sentence"},{"id":"T103","span":{"begin":262,"end":371},"obj":"Sentence"},{"id":"T104","span":{"begin":372,"end":630},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157)."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T36","span":{"begin":20,"end":23},"obj":"Phenotype"},{"id":"T37","span":{"begin":265,"end":291},"obj":"Phenotype"},{"id":"T38","span":{"begin":343,"end":359},"obj":"Phenotype"}],"attributes":[{"id":"A36","pred":"hp_id","subj":"T36","obj":"http://purl.obolibrary.org/obo/HP_0020103"},{"id":"A37","pred":"hp_id","subj":"T37","obj":"http://purl.obolibrary.org/obo/HP_0033141"},{"id":"A38","pred":"hp_id","subj":"T38","obj":"http://purl.obolibrary.org/obo/HP_0002721"}],"text":"COVID‐19 associated IPA was classified according to the (modified) 3 AspICU algorithm 7 with the addition that positive galactomannan (≥1) from BALF or TA, or two consecutively but separately drawn positive serum samples (≥1) were accepted as entry criterion. 8 Severe SARS‐CoV2 infection with ARDS was accepted as host criterion (acquired immunodeficiency) (Table 1). This study was carried out in accordance with the ethical principles reflected in the Declaration of Helsinki 9 and was approved by the ethic committee of the University Hospital of Cologne (Identifier of the University of Cologne Ethics Committee 20‐1157)."}